Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.

Data

Health Data

Aitia

Aitia's headquarters in Somerville, MA, United States

Colin Hill

Isabelle Caffry

Apoorva Karkhanis

Igor Nemer

So-Youn Shin

McLaren Gould

Ken Levine

Jan Berger

Bruce Church

Description

People (13)

Colin Hill

Bruce Church

QIAN DU

Ken Levine

McLaren Gould

Jerome Windsor, PharmD, MBA

Apoorva Karkhanis

Michelle Brauer

srujan c

Yongan Zhao

Isabelle Caffry

Cecilia Washburn

Levina Moy